Please assess the completion status of the following clinical trial:

Trial Title: Dolutegravir in Pregnant HIV Mothers and Their Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.~2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.~3. Women aged 18 years or older~4. Pregnant ( ≥28 weeks gestation by best available gestation estimation)~5. Untreated HIV infection in late pregnancy~Exclusion Criteria:~1. Received any antiretroviral drugs in previous 12 months~2. Ever received integrase inhibitors~3. Previous documented failure of an NNRTI-containing ART regimen, previous EFV-associated toxicity or other history of ARV use that would preclude randomisation based on investigator judgement~4. Serum haemoglobin \<8.0 g/dl~5. eGFR\<50 ml/min\*~6. Elevations in serum levels of alanine aminotransferase (ALT) \>5 times the upper limit of normal (ULN) or ALT \>3xULN and bilirubin \>2xULN (with \>35% direct bilirubin).~7. History or clinical suspicion of unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hyperbilirubinaemia, oesophageal or gastric varices or persistent jaundice).~8. Severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or liver abnormalities (e.g. grade 2 or above proteinuria,, total bilirubin, ALT or AST)\* at the time of enrolment~9. Paternal objection for infant participation in DTG arm (where disclosure has taken - applies to Uganda site only~10. Medical, psychiatric or obstetric condition that might affect participation in the study based on investigator judgement~11. Receiving any of the following medications (current or within past 2 weeks): anti-epileptic drugs, TB therapy, or other drugs known to significantly interact with either DTG or EFV

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dolutegravir (Type: EXPERIMENTAL): Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
- Standard of Care (EFV + 2 NRTI backbone) (Type: ACTIVE_COMPARATOR): Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).

Based on this trial design, predict the completion outcome and termination type (if applicable).